Sera Prognostics CFO sells $19,593 in inventory

SALT LAKE CITY—Sera Prognostics, Inc. (NASDAQ:SERA) Chief Monetary Officer Austin Aerts just lately offered shares of the corporate’s Class A standard inventory, in keeping with a current submitting with the Securities and Change Fee. The corporate, presently valued at $216 million, has seen its inventory decline over 23% up to now week, in keeping with InvestingPro knowledge.

The transaction, which occurred on January 10, 2025, concerned the sale of two,431 shares at a weighted common value of $8.06, producing a complete of $19,593. The shares have been offered in a number of transactions at costs starting from $7.99 to $8.13. Because the sale, the inventory has fallen to $6.37, although InvestingPro evaluation signifies the corporate maintains a robust money place, with liquid property exceeding short-term obligations.

Following this sale, Aerts retains direct possession of 283,325 shares of Sera Prognostics. The transaction was executed beneath a Rule 10b5-1 buying and selling plan that Aerts adopted on Could 22, 2024, permitting for prearranged inventory transactions. InvestingPro’s complete evaluation, together with Truthful Worth estimates and eight further key insights, is on the market within the Professional Analysis Report.

In different current information, Sera Prognostics disclosed in an SEC submitting that the Society for Maternal Fetal Medication (SMFM) has revealed an summary with topline outcomes from the PRIME research. The research, specializing in enhancing neonatal outcomes by means of prematurity threat evaluation mixed with scientific interventions, is about to be introduced intimately quickly. Following the presentation, Sera Prognostics plans to host a convention name and dwell audio webcast for an in-depth dialogue of the PRIME research’s outcomes.

Within the firm’s current financials, there was a lower in internet income to $29,000 from $42,000. Working bills rose by 8% to $8.9 million, and the web loss elevated by 10% to $7.9 million. Regardless of these numbers, Sera Prognostics maintains a robust money reserve of $74.3 million, projected to maintain operations into 2027.

The corporate is placing a highlight on its PreTRM take a look at, aiming to reinforce its adoption to deal with rising preterm delivery charges within the U.S. CEO Evguenia Lindgardt underlined the importance of the forthcoming publication of the PRIME scientific research outcomes, that are anticipated to play a vital function in securing payer help and influencing scientific tips. These current developments kind the spine of Sera Prognostics’ technique for industrial development and sustaining stable money reserves within the coming years.

This text was generated with the help of AI and reviewed by an editor. For extra data see our T&C.